10 Best Cancer Stocks to Invest in for Long-Term Gains

Page 9 of 9

1. Insmed Incorporated (NASDAQ:INSM)

Number of Hedge Fund Holders: 72

Total 5-Year Return: 198.95%

Insmed Incorporated (NASDAQ:INSM) tops our list for being one of the best cancer stocks. It is a biopharmaceutical company focused on developing and marketing treatments for serious and rare diseases, including cancer. It generates revenue through global drug sales and licensing. In oncology, the company is developing rhIGFBP-3, a protein that may enhance chemotherapy effectiveness in breast cancer, aiming to improve treatment outcomes for patients with high unmet medical needs.

In Q4 2024, Insmed Incorporated (NASDAQ:INSM)’s total revenue rose 24.8% year-over-year to $104.4 million, bringing full-year 2024 revenue to $363.7 million, a 19.2% increase. This growth was primarily driven by the continued strong uptake of ARIKAYCE, especially in Japan (up 33.4%) and Europe/Rest of World (up 38.8%), supported by successful market expansion and increasing adoption for treating refractory MAC lung disease. In the U.S., ARIKAYCE revenue grew 13.7% to $254.8 million.

Insmed Incorporated (NASDAQ:INSM) reported a widened net loss of $ 235.5 million in Q4 2024, or $1.32 per share, compared to $186.1 million in Q4 2023. The full-year net loss deepened to $913.8 million, or $5.57 per share, from $749.6 million in 2023. R&D expenses rose to $598.4 million due to increased investment in late-stage programs and launch readiness. SG&A expenses also increased significantly to $461.1 million, reflecting commercial scale-up ahead of the brensocatib launch.

Brensocatib received FDA Priority Review with a PDUFA date of August 12, 2025, and a potential U.S. launch in Q3 2025. The pipeline remains active, with multiple late-stage readouts anticipated in 2025–2026, including label expansion for ARIKAYCE and trials for TPIP in PAH. Additionally, Insmed Incorporated (NASDAQ:INSM) is expanding into gene therapy, with an IND cleared for its DMD program and progress reported in ALS and Stargardt disease.

Overall, INSM ranks first among the 10 best cancer stocks to invest in for long term gains. While we acknowledge the potential of cancer companies, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than INSM but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. 

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9